G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9.15 USD -3.58% Market Closed
Market Cap: 476.1m USD
Have any thoughts about
GH Research PLC?
Write Note

Intrinsic Value

GHRS's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one GHRS stock under the Base Case scenario is 4.27 USD. Compared to the current market price of 9.15 USD, GH Research PLC is Overvalued by 53%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GHRS Intrinsic Value
4.27 USD
Overvaluation 53%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
GH Research PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GHRS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GHRS?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about GH Research PLC

Provide an overview of the primary business activities
of GH Research PLC.

What unique competitive advantages
does GH Research PLC hold over its rivals?

What risks and challenges
does GH Research PLC face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for GH Research PLC.

Provide P/S
for GH Research PLC.

Provide P/E
for GH Research PLC.

Provide P/OCF
for GH Research PLC.

Provide P/FCFE
for GH Research PLC.

Provide P/B
for GH Research PLC.

Provide EV/S
for GH Research PLC.

Provide EV/GP
for GH Research PLC.

Provide EV/EBITDA
for GH Research PLC.

Provide EV/EBIT
for GH Research PLC.

Provide EV/OCF
for GH Research PLC.

Provide EV/FCFF
for GH Research PLC.

Provide EV/IC
for GH Research PLC.

Show me price targets
for GH Research PLC made by professional analysts.

What are the Revenue projections
for GH Research PLC?

How accurate were the past Revenue estimates
for GH Research PLC?

What are the Net Income projections
for GH Research PLC?

How accurate were the past Net Income estimates
for GH Research PLC?

What are the EPS projections
for GH Research PLC?

How accurate were the past EPS estimates
for GH Research PLC?

What are the EBIT projections
for GH Research PLC?

How accurate were the past EBIT estimates
for GH Research PLC?

Compare the revenue forecasts
for GH Research PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of GH Research PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of GH Research PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of GH Research PLC compared to its peers.

Compare the P/E ratios
of GH Research PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing GH Research PLC with its peers.

Analyze the financial leverage
of GH Research PLC compared to its main competitors.

Show all profitability ratios
for GH Research PLC.

Provide ROE
for GH Research PLC.

Provide ROA
for GH Research PLC.

Provide ROIC
for GH Research PLC.

Provide ROCE
for GH Research PLC.

Provide Gross Margin
for GH Research PLC.

Provide Operating Margin
for GH Research PLC.

Provide Net Margin
for GH Research PLC.

Provide FCF Margin
for GH Research PLC.

Show all solvency ratios
for GH Research PLC.

Provide D/E Ratio
for GH Research PLC.

Provide D/A Ratio
for GH Research PLC.

Provide Interest Coverage Ratio
for GH Research PLC.

Provide Altman Z-Score Ratio
for GH Research PLC.

Provide Quick Ratio
for GH Research PLC.

Provide Current Ratio
for GH Research PLC.

Provide Cash Ratio
for GH Research PLC.

What is the historical Revenue growth
over the last 5 years for GH Research PLC?

What is the historical Net Income growth
over the last 5 years for GH Research PLC?

What is the current Free Cash Flow
of GH Research PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for GH Research PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
GH Research PLC

Current Assets 152.9m
Cash & Short-Term Investments 151.3m
Other Current Assets 1.6m
Non-Current Assets 54.1m
Long-Term Investments 53.2m
PP&E 896k
Current Liabilities 7.8m
Accounts Payable 2.6m
Other Current Liabilities 5.2m
Non-Current Liabilities 497k
Long-Term Debt 497k
Efficiency

Earnings Waterfall
GH Research PLC

Revenue
0 USD
Operating Expenses
-34.1m USD
Operating Income
-34.1m USD
Other Expenses
6.8m USD
Net Income
-27.3m USD

Free Cash Flow Analysis
GH Research PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GHRS Profitability Score
Profitability Due Diligence

GH Research PLC's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

32/100
Profitability
Score

GH Research PLC's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

GHRS Solvency Score
Solvency Due Diligence

GH Research PLC's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

GH Research PLC's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GHRS Price Targets Summary
GH Research PLC

Wall Street analysts forecast GHRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GHRS is 32.64 USD with a low forecast of 18.18 USD and a high forecast of 42 USD.

Lowest
Price Target
18.18 USD
99% Upside
Average
Price Target
32.64 USD
257% Upside
Highest
Price Target
42 USD
359% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GHRS?

Click here to dive deeper.

Dividends

GH Research PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for GHRS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

GH Research PLC

Country

Ireland

Industry

Pharmaceuticals

Market Cap

476.1m USD

Dividend Yield

0%

Description

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

Contact

LEINSTER
DUBLIN
28 Baggot Street
+35341763603200.0

IPO

2021-06-25

Employees

9

Officers

Co-Founder & Non-Executive Chairman of the Board
Mr. Florian Schonharting M.Sc. (Econ)
Chief Executive Officer
Dr. Velichka Valcheva M.D.
Co-Founder & MD of Ireland
Mr. Magnus Halle
Vice President of Finance
Ms. Julie Ryan F.C.A.
Chief Operating Officer
Mr. Aaron Cameron M.B.A.

See Also

Discover More
What is the Intrinsic Value of one GHRS stock?

The intrinsic value of one GHRS stock under the Base Case scenario is 4.27 USD.

Is GHRS stock undervalued or overvalued?

Compared to the current market price of 9.15 USD, GH Research PLC is Overvalued by 53%.

Back to Top